BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 31212178)

  • 41. Synthesis, design, and antiproliferative evaluation of 6-(N-Substituted-methyl)pyrazolo[3,4-d]pyrimidines as the potent anti-leukemia agents.
    Chung CY; Li SM; Zeng WZ; Uramaru N; Huang GJ; Juang SH; Wong FF
    Bioorg Chem; 2024 Jul; 148():107424. PubMed ID: 38728908
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, Synthesis,
    Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
    Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.
    Othman IMM; Alamshany ZM; Tashkandi NY; Gad-Elkareem MAM; Anwar MM; Nossier ES
    Bioorg Chem; 2021 Sep; 114():105078. PubMed ID: 34161878
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo[1,5-c]quinazolines as potential EGFR inhibitors.
    Ansari AJ; Joshi G; Yadav UP; Maurya AK; Agnihotri VK; Kalra S; Kumar R; Singh S; Sawant DM
    Bioorg Chem; 2019 Dec; 93():103314. PubMed ID: 31590041
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
    Alkamaly OM; Altwaijry N; Sabour R; Harras MF
    Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy.
    Ibrahim TS; Hawwas MM; Taher ES; Alhakamy NA; Alfaleh MA; Elagawany M; Elgendy B; Zayed GM; Mohamed MFA; Abdel-Samii ZK; Elshaier YAMM
    Bioorg Chem; 2020 Dec; 105():104352. PubMed ID: 33080494
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
    Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
    Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity.
    Eissa AAM; Aljamal KFM; Ibrahim HS; Abdelrasheed Allam H
    Bioorg Chem; 2021 Nov; 116():105318. PubMed ID: 34488123
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pyrazole derivatives as potent EGFR inhibitors: synthesis, biological evaluation and
    Bayoumi NA; El-Shehry MF
    Future Med Chem; 2022 Dec; 14(23):1755-1769. PubMed ID: 36524436
    [No Abstract]   [Full Text] [Related]  

  • 51. Design, synthesis and molecular modeling studies of 2-styrylquinazoline derivatives as EGFR inhibitors and apoptosis inducers.
    Amin NH; Elsaadi MT; Zaki SS; Abdel-Rahman HM
    Bioorg Chem; 2020 Dec; 105():104358. PubMed ID: 33074119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design of molecular hybrids of phthalimide-triazole agents with potent selective MCF-7/HepG2 cytotoxicity: Synthesis, EGFR inhibitory effect, and metabolic stability.
    Ihmaid SK; Alraqa SY; Aouad MR; Aljuhani A; Elbadawy HM; Salama SA; Rezki N; Ahmed HEA
    Bioorg Chem; 2021 Jun; 111():104835. PubMed ID: 33798850
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
    Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
    Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAF
    Abou-Zied HA; Beshr EAM; Gomaa HAM; Mostafa YA; Youssif BGM; Hayallah AM; Abdel-Aziz M
    Arch Pharm (Weinheim); 2023 Apr; 356(4):e2200464. PubMed ID: 36526595
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, synthesis, apoptotic, and antiproliferative effects of 5-chloro-3- (2-methoxyvinyl)-indole-2-carboxamides and pyrido[3,4-b]indol-1-ones as potent EGFR
    Al-Wahaibi LH; Mohammed AF; Abdel Rahman FES; Abdelrahman MH; Gu X; Trembleau L; Youssif BGM
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2218602. PubMed ID: 37254958
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
    Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
    Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
    Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
    Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents.
    Alam R; Wahi D; Singh R; Sinha D; Tandon V; Grover A; Rahisuddin
    Bioorg Chem; 2016 Dec; 69():77-90. PubMed ID: 27744115
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
    Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B
    Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules.
    Abou-Zied HA; Youssif BGM; Mohamed MFA; Hayallah AM; Abdel-Aziz M
    Bioorg Chem; 2019 Aug; 89():102997. PubMed ID: 31136902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.